NASDAQ:MTEM
Molecular Templates Inc Stock News
$1.67
-0.0550 (-3.19%)
At Close: May 03, 2024
Molecular Templates gains 8% on FDA Fast Track tag for MT-6402
01:51pm, Thursday, 18'th Nov 2021 Seeking AlphaMolecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402
01:00pm, Thursday, 18'th Nov 2021 Intrado Digital Media
AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1.
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Misses Revenue Estimates
05:25pm, Monday, 15'th Nov 2021 Zacks Investment Research
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -68.75% and -84.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Misses Revenue Estimates
01:55pm, Monday, 15'th Nov 2021
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -68.75% and -84.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th
Molecular Templates EPS misses by $0.19, misses on revenue
01:35pm, Monday, 15'th Nov 2021 Seeking AlphaMolecular Templates, Inc. Reports Third Quarter 2021 Financial Results
12:30pm, Monday, 15'th Nov 2021 GlobeNewswire Inc.
AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discov
Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results
12:30pm, Monday, 15'th Nov 2021 Intrado Digital Media
AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the third quarter of 2021.
4 Small Drug Stocks That Hold Promise Despite Industry Challenges
09:05am, Wednesday, 27'th Oct 2021
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.
Wall Street Analysts Predict a 98% Upside in Molecular Templates Inc. (MTEM): Here's What You Should Know
10:11am, Tuesday, 12'th Oct 2021
The average of price targets set by Wall Street analysts indicates a potential upside of 98.3% in Molecular Templates Inc. (MTEM). While the effectiveness of this highly sought-after metric is questio
Molecular Templates Inc. (MTEM) Moves 11.8% Higher: Will This Strength Last?
05:24am, Wednesday, 22'nd Sep 2021
Molecular Templates Inc. (MTEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
Molecular Templates Inc. (MTEM) Reports Q2 Loss, Lags Revenue Estimates
09:35pm, Thursday, 12'th Aug 2021
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -115.38% and -50.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st
Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results
04:30pm, Thursday, 12'th Aug 2021
AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discover
Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors
08:00am, Friday, 09'th Jul 2021
AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery
Molecular Templates Inc. (MTEM) Reports Q1 Loss, Lags Revenue Estimates
08:26pm, Thursday, 13'th May 2021
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -282.14% and -89.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the s
Molecular Templates, Inc. Reports First Quarter 2021 Financial Results
04:30pm, Thursday, 13'th May 2021
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery